Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or cetuximab as a strategy to overcome tumor ...
Purple Biotech Ltd. announced significant progress in its clinical development pipeline during the AACR Annual Meeting 2025, providing updates on its therapies CM24 and NT219, and progressing toward ...
Purple Biotech reports positive trial results for CM24 and NT219, advancing toward biomarker-driven studies and expanding its oncology pipeline. Purple Biotech Ltd. announced positive results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results